CompletedPhase 1NCT05078879
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Studying Congenital neutropenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- David H McDermott, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Empagliflozin(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2021 – 2025
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05078879 on ClinicalTrials.gov